The Effect of Fluoxetine on Progression in Progressive Multiple Sclerosis: A Double-Blind, Randomized, Placebo-Controlled Trial

Preclinical studies suggest that fluoxetine may have neuroprotective properties. In this pilot study forty-two patients with secondary or primary progressive MS were randomized to receive fluoxetine 20 mg twice daily or placebo for 2 years. Every 3 months the Expanded Disability Status Scale (EDSS),...

Descripción completa

Detalles Bibliográficos
Autores principales: Mostert, Jop, Heersema, Thea, Mahajan, Manju, Van Der Grond, Jeroen, Van Buchem, Mark A., De Keyser, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747490/
https://www.ncbi.nlm.nih.gov/pubmed/23984093
http://dx.doi.org/10.1155/2013/370943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747490/
https://www.ncbi.nlm.nih.gov/pubmed/23984093
http://dx.doi.org/10.1155/2013/370943

Ejemplares similares